Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig 1 , Mario Boccadoro 2 , Philippe Moreau 3 , Jesus San-Miguel 4 , Michele Cavo 5 , Charlotte Pawlyn 6 , Sonja Zweegman 7 , Thierry Facon 8 , Christoph Driessen 9 , Roman Hajek 10 , Melitios A Dimopoulos 11 , Francesca Gay 2 , Hervé Avet-Loiseau 12 , Evangelos Terpos 11 , Niklas Zojer 13 , Mohamad Mohty 14 , Maria-Victoria Mateos 15 , Hermann Einsele 16 , Michel Delforge 17 , Jo Caers 18 , Katja Weisel 19 , Graham Jackson 20 , Laurent Garderet 21 , Monika Engelhardt 22 , Niels van de Donk 7 , Xavier Leleu 23 , Hartmut Goldschmidt 24 , Meral Beksac 25 , Inger Nijhof 7 , Niels Abildgaard 26 , Sara Bringhen 2 , Pieter Sonneveld 27
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy.
Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma.
Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations.
Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
CITA DEL ARTÍCULO Leukemia . 2020 Aug 19. doi: 10.1038/s41375-020-01016-0